R&D
pharmaphorum podcast episode 98

Turning drug development on its head

Drug discovery is usually a goal-driven and iterative process, as researchers look for innovative new routes to target particular diseases and study those diseases in afflicted patients to learn ho

Patients
pharmaphorum podcast episode 95

Partnering for holistic care

In a new episode of the pharmaphorum podcast, editor-in-chief Jonah Comstock speaks with Eugene Borukhovich, co-founder and COO of YourCoach Health, and Lyndi Hirsch, SVP of marketing strat

Patients
pharmaphorum podcast episode 95

Partnering for holistic care

In a new episode of the pharmaphorum podcast, editor-in-chief Jonah Comstock speaks with Eugene Borukhovich, co-founder and COO of YourCoach Health, and Lyndi Hirsch, SVP of marketing strat

Sales & Marketing

Sales & Marketing
pharmaphorum podcast episode 90

Changing personnel dynamics in the pharma world

An economic downturn always has effects that reverberate across an industry, and perhaps one of the most visible reverberations is in the realm of personnel - more layoffs and less hiring a

Digital

Market Access

Newsletters and Deep Dive
digital magazine

Oncology

Patients

Patients
pharmaphorum podcast episode 95

Partnering for holistic care

In a new episode of the pharmaphorum podcast, editor-in-chief Jonah Comstock speaks with Eugene Borukhovich, co-founder and COO of YourCoach Health, and Lyndi Hirsch, SVP of marketing strat

Patients
pharmaphorum podcast episode 91

Clinical trial diversity: An update

Editor-in-chief Jonah Comstock welcomes back returning guest Dr Jennifer Jones-McMeans, divisional vice president for global affairs for Abbott’s vascular business.

R&D

R&D
pharmaphorum podcast episode 98

Turning drug development on its head

Drug discovery is usually a goal-driven and iterative process, as researchers look for innovative new routes to target particular diseases and study those diseases in afflicted patients to learn ho

R&D
pharmaphorum podcast episode 93

Alzheimer’s drugs: An overview and update

When we covered JP Morgan in January, over and over we heard that neurodegenerative diseases, especially Alzheimer’s, were going to be one of the most exciting spaces in pharma this year.